Clinical Trials

The Tumor Immunotherapy Program has a number of studies that are currently recruiting patients. For information about how to be referred to one of these studies, please contact us.

Currently Recruiting

  • TILs-001-DC

    A Phase I Study evaluating the feasibility and safety of infusion of Re-StimulatedAutologous tumor-infiltrating lymphocytes (TILs) followed by low-dose interleukin-2 therapy in patients with platinum resistant high grade serous ovarian, fallopian tube, or primary peritoneal cancer

    Eligible Tumour Type(s): Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT01883297

    https://clinicaltrials.gov/ct2/show/NCT01883297

  • 1301-02

    Phase 1b Study of NY-ESO-1 specific TCR gene transduced autologous T lymphocytes in patients with solid tumors

    Eligible Tumour Type(s): Solid Cancer
    Sponsor: In-house (in collaboration with Takara Bio Inc)
    Principal Investigator: Marcus Butler
    NCT#: NCT02869217

    https://clinicaltrials.gov/ct2/show/NCT02869217

  • TILs-003-Meso

    Phase I/II study evaluating the infusion of tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with malignant pleural mesothelioma)

    Eligible Tumour Type(s): Malignant Pleural Mesothelioma
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT02414945

    https://clinicaltrials.gov/ct2/show/NCT02414945?term=TILs-003-Meso&rank=1

  • ACTIVATE

    Phase Ib trial of pembrolizumab administered in combination or following adoptive cell therapy: A multiple cohort study

    Eligible Tumour Type(s): Metastatic Melanoma, Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT02811497

    https://clinicaltrials.gov/ct2/show/NCT03158935

  • METADUR

    An open-label, phase II basket study of a hypomethylating agent azacitidine and durvalumab (anti-PDL1) in advanced solid tumors.

    Eligible Tumour Type(s): Breast Cancer, Colorectal Cancer, Ovarian Cancer
    Sponsor: In-House
    Principal Investigator: Lillian Siu
    NCT#: NCT02811497

    https://clinicaltrials.gov/ct2/show/NCT02811497

  • Phase I Study of Autologous Acute Myelogenous Leukemia (AML) Cells Containing Lentivirus Engineering

    This is a phase 1 study (the first stage in testing a new treatment to see how safe and tolerable the treatment is) which will include patients with acute myeloid leukemia (AML) that has either returned or has a more than a 70% chance of coming back and cannot have a bone marrow transplant.

    This study will see whether modifying a patient's AML cells to produce IL-12 and giving it back to the patient is safe and useful in patients with AML that cannot have bone marrow transplants.

    Eligible Tumour Type(s): Acute Myeloid Leukemia (AML)
    Sponsor: In-House
    Principal Investigator: Dr Mark Minden
    NCT#: NCT02483312

    https://clinicaltrials.gov/ct2/show/NCT02483312

  • Role of microbiome as a biomarker in loco-regionally-advanced oropharyngeal squamous cell carcinoma (ROMA)
    Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
    Sponsor: In-house
    Principal Investigator: Lillian Siu and Anna Spreafic
    NCT#: N/A

Closed Recruiting

  • TILs-002-MEL

    Phase II Study evaluating the infusion of autologous tumor-infiltrating lymphocytes (TILs) and low-dose interleukin-2 (IL-2) therapy following a preparative regimen of non-myeloablative lymphodepletion using cyclophosphamide and fludarabine in patients with metastatic melanoma.

    Eligible Tumour Type(s): Metastatic Melanoma
    Sponsor: In-House
    Principal Investigator: Marcus Butler
    NCT#: NCT01883323

    https://clinicaltrials.gov/ct2/show/NCT01883323?term=TILs-002-MEL&rank=1

  • INSPIRE

    INvestigator-initiated Phase II Study of pembrolizumab immunological response evaluation

    Eligible Tumour Type(s): Metastatic Melanoma, Ovarian Cancer, Solid Cancer, Squamous Cell Cancer of the Head and Neck, Triple Negative Breast Cancer
    Sponsor: In-House
    Principal Investigator: Lillian Siu
    NCT#: NCT02644369

    https://clinicaltrials.gov/ct2/show/NCT02644369

  • PRIMED

    Window of opportunity study for patients with resectable squamous cell carcinoma of the oral cavity who are considered suitable for curative-intent surgical resection, with pre-operative mocetinostat and durvalumab. Eligible Tumour Type(s): squamous cell carcinoma of the oral cavity

    Eligible Tumour Type(s): Squamous Cell Carcinoma of the Oral Cavity
    Sponsor: In-House
    Principal Investigator: Lillian Siu
    NCT#: NCT02993991

Pages